Interrelationship of Circulating Matrix Metalloproteinase-9, TNF-α, and OPG/RANK/RANKL Systems in COPD Patients with Osteoporosis

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 10, Issue 6, 2013, Pages 650-656

  Zhang, Pei Fang ^a,b   Pan, Lei ^c   Luo, Zhi Yang ^b   Zhao, Hai Jin ^a   Cai, Shao Xi ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

^c Department of Traumatic Spinal Surgery   (China)

Author keywords

Bone mineral density; COPD; Matrix metalloproteinase; Osteoporosis; Pathogenesis

Indexed keywords

GELATINASE B; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BONE DENSITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMUR NECK; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUMBAR SPINE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SMOKING;

AGED; BODY MASS INDEX; BONE DENSITY; CASE-CONTROL STUDIES; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OSTEOPOROSIS; OSTEOPROTEGERIN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84887856675     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2013.813928     Document Type: Article

References (38)

1. Schols AM, Broekhuizen R, Weling-Scheepers CA, et al. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005 Jul; 82(1):53-59.
2. Agusti AG, Soriano JB. COPD as a systemic disease. COPD 2008; 5:133-138.
3. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Gold executive summary. Am J Respir Crit Care Med 2007; 176:532-555.
4. Kjensli A, Mowinckel P, Ryg MS, et al. Low bone mineral density is related to severity of chronic obstructive pulmonary disease. Bone 2007; 40:493-497.
5. Vrieze A, de Greef MH, Wykstra PJ, et al. Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat-free mass. Osteoporos Int 2007; 18:1197-1202.
6. Duckers JM, Evans BA, Fraser WD, et al. Low bone mineral density in men with chronic obstructive pulmonary disease. Respiratory Research 2011; 12:101.
7. Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med. 2003 Jan; 114(1):10-14.
8. Leech JA, Dulberg C, Kellie S, et al. Relationship of lung function to severity of osteoporosisin women. Am Rev Respir Dis 1990 Jan; 141(1): 68-71.
9. Bolton CE, Stone MD, Edwards PH, et al. Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. Chron Respir Dis 2009; 6(2): 81-87.
10. Muroski ME, Roycik MD, Newcomer RG, Van den Steen PE, Opdenakker G, Monroe HR, Sahab ZJ, Sang QX. Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol. 2008 Feb; 9(1):34-46.
11. Tanaka H, Miyazaki N, Oashi K, et al. Sputum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio in acute asthma. J Allergy Clin Immunol 2000; 105:900-905.
12. Engsig MT, Chen QJ, Vu TH, et al. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol 2000; 151(4):879-889.
13. Hill PA, Murphy G, Docherty AJ, et al. The eff ects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identifi cation of MMPs and TIMP-1 in isolated osteoclasts. J Cell Sci 1994 Nov; 107 (Pt 11)3055-3064.
14. McLean RR. Proinflammatory Cytokines and Osteoporosis. Current Osteoporosis Reports 2009; 7:134-139.
15. Pinto-Plata V, Casanova C, M?lerova H, et al. Infl ammatory and repair serum biomarker pattern. Association to clinical outcomes in COPD. Respir Res 2012; 13(1):71.
16. Bon JM, Leader JK, Weissfeld JL, et al. The infl uence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease. PLoS One 2009 Aug 31; 4(8):e6865.
17. Mundy GR. Osteoporosis and Infl ammation. Nutrition Reviews 2007; 65:S147-S151
18. Ragab AA, Nalepka JL, Bi Y, et al. Cytokines synergistically induce osteoclast diff erentiation: support by immortalized or normal calvarial cells. Am J Physiol Cell Physiol 2002; 283:C679-687.
19. Kwan TS, Padrines M, Th ?leyre S, et al. IL-6, RANKL, TNF-?/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004; 15:49-60.
20. Simonet WS, Lacey D, Dunstan C, et al. Osteoprogerin:a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
21. Hacievliyagil SS, Gunen H, Mutlu LC, Karabulut AB, Temel I. Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. Respir Med 2006 May; 100(5):846-854.
22. Xie B, Laouar A, Huberman E. Autocrine regulation of macrophage diff erentiation and 92-kDa gelatinase production by tumor necrosis factor-Alpha via alpha5 beta1 integrin in HL-60 cells. J Biol Chem 1998 May 8; 273(19):11583-11588.
23. Xie B, Laouar A, Huberman E. Fibronectin-mediated cell adhesion is required for induction of 92-kDa type IV collagenase/gelatinase (MMP-9) gene expression during macrophage diff erentiation. The signaling role of protein kinase C-beta. J Biol Chem 1998 May 8; 273(19):11576-11582.
24. Jones PW, Harding G, Berry P, et al. Development and fi rst validation of the COPD Assessment Test. Eur Respir J 2009 Sep; 34(3):648-654.
25. Kanis JA, Melton LJ 3rd, Christiansen C, et al. The diagnosis of osteoporosis.J Bone Miner Res. 1994 Aug; 9(8):1137-1141.
26. Higashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, Tohda Y. Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med 2009; 103(8):1231-1238.
27. Olafsdottir IS, Janson C, Lind L, Hulthe J, Gunnbjornsdottir M, Sundstrom J. Serum levels of matrix metalloproteinase-9, tissue inhibitors of metalloproteinase-1 and their ratio are associated with impaired lung function in the elderly: a population-based study. Respirology 2010; 15(3):530-535.
28. Qin J, Yang NL. Relationship between serum matrix metalloproteinase-9 and tissue inhibitors of metalloproteinase-1 and bone mineral density in postmenopausal women. Chin J Osteoporos 2008; 14(4):245-248.
29. Nyman JS, Lynch CC, Perrien DS, et al. Diff erential eff ects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of bone. J Bone Miner Res 2011 Jun; 26(6):1252-1260.
30. Bon JM, Zhang Y, Duncan SR, Pilewski JM, Zaldonis D, Zeevi A, McCurry KR, Greenspan SL, Sciurba FC. Plasma infl ammatory mediators associated with bone metabolism in COPD. COPD 2010 Jun; 7(3):186-191.
31. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic infl ammation: a systematic review and a meta-Analysis. Th orax 2004 Jul; 59(7):574-580.
32. Kochetkova EA, Uga? LG, Ma?strovskaia IuV, Buria KA, Nevzorova VA. Role of matrix metalloproteinase-9 in the pathogenesis of osteoporosis in patients with chronic obstructive pulmonary disease. Ter Arkh 2012; 84(8):37-40.
33. Hozumi A, Nishimura Y, Nishiuma T, Kotani Y, Yokoyama M. Induction of MMP-9 in normal human bronchial epithelial cells by TNF-Alpha via NF-kappa B-mediated pathway. Am J Physiol Lung Cell Mol Physiol 2001 Dec; 281(6):L1444- 1452.
34. Bai P, Sun Y, Jin J, Hou J, Li R, Zhang Q, Wang Y. Disturbance of the OPG/RANK/RANKL pathway and systemic infl ammation in COPD patients wiThemphysema and osteoporosis. Respir Res 2011 Dec 16; 12:157.
35. Nakamura M, Udagawa N, Matsuura S, et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 2003; 144(12):5441-5449.
36. Nakamichi Y, Udagawa N, Kobayashi Y, et al. Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts. J Immunol 2007; 178(1):192-200.
37. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001 Dec; 142(12):5050-5055.
38. Biskobing DM. COPD and osteoporosis. Chest 2002; 121(2):609-20.